Sigma Healthcare Limited (ASX:SIG)
Australia
· Delayed Price · Currency is AUD | Market Cap | 31.86B |
| Revenue (ttm) | 9.55B |
| Net Income (ttm) | 599.81M |
| Shares Out | 11.50B |
| EPS (ttm) | 0.05 |
| PE Ratio | 52.10 |
| Forward PE | 39.74 |
| Dividend | 0.01 (0.47%) |
| Ex-Dividend Date | Mar 4, 2026 |
| Volume | 7,099,369 |
| Average Volume | 11,959,766 |
| Open | 2.760 |
| Previous Close | 2.770 |
| Day's Range | 2.740 - 2.780 |
| 52-Week Range | 2.580 - 3.280 |
| Beta | 0.15 |
| RSI | 49.84 |
| Earnings Date | May 15, 2026 |
About Sigma Healthcare
Sigma Healthcare Limited operates as a retail pharmacy franchisor and pharmaceutical wholesale and distributor to community pharmacies primarily in Australia. It offers support services to a network of franchised retail pharmacies; third and fourth party logistics services to pharmaceutical manufacturers and other supplier partners; and health services. The company operates stores under the Chemist Warehouse, Amcal, and Discount Drug stores brand names. It also offers products through online. The company was founded in 1912 and is headquartered... [Read more]
Financial Performance
In fiscal year 2025, Sigma Healthcare's revenue was 6.00 billion, an increase of 82.18% compared to the previous year's 3.29 billion. Earnings were 529.91 million, a decrease of -2.05%.
Financial StatementsNews
Sigma Healthcare Earnings Call Transcript: H1 2026
Revenue grew 15% year-over-year, with strong domestic and international sales, and normalized EBIT up 18.7%. Integration synergies and disciplined cost control supported margin expansion, while GLP-1 medicines drove significant sales growth.
Sigma Healthcare Transcript: AGM 2025
The AGM highlighted strong financial growth post-merger, upgraded synergy targets, and robust governance enhancements. Shareholders approved all resolutions, including director reelections and remuneration reports, while the board addressed integration, remuneration, and related party governance in detail.
Sigma Healthcare Earnings Call Transcript: H2 2025
Strong post-merger results with revenue up 82% and normalized EBIT up 41%. Store network expansion, own brand growth, and upgraded synergy targets drive performance, while integration and competitive pressures remain key focus areas.
Sigma Healthcare Transcript: EGM 2025
Shareholders approved key resolutions for a transformative merger with Chemist Warehouse, including new board appointments, governance frameworks for related party transactions, and changes to executive equity plans. The merger aims to create a leading pharmacy group with significant cost synergies and growth opportunities.
Sigma Healthcare Earnings Call Transcript: H1 2025
Revenue and profit surged on the back of the new Chemist Warehouse contract, with normalized NPAT up over 300% and EBIT up 20% year-over-year. Gross margin remains under pressure, but cost discipline and operational leverage are improving profitability. Guidance for FY25 normalized EBIT is AUD 50–60 million.
Sigma Healthcare Transcript: AGM 2024
Sigma Healthcare Earnings Call Transcript: H2 2024
Sigma Healthcare posts record jump on $5.8 bln merger with Chemist Warehouse
Shares in Australia's Sigma Healthcare surged more than 76% in early trade on Wednesday to post a record intraday jump, after the company said on Monday it would merge with Chemist Warehouse Group to ...